Numerous studies showed a TPL2-driven MEK/ERK1/2 activation pathway relevant in a number of cancers although the tumor-promoting or anti-tumor effect of TPL2 involvement is varying from one to another (Lee et al., 2015[30]). This evidence concerns the gene MAP3K8 and cancer.